Please login to the form below

Not currently logged in
Email:
Password:

Merck acquires experimental MS drug

The worldwide exclusive rights to PI-2301, an experimental multiple sclerosis drug, have been acquired by Merck

The worldwide exclusive development and commercialisation rights to PI-2301, an experimental drug for multiple sclerosis (MS), have been acquired by Merck (known as EMD Chemicals in the US and Canada).

PI-2301 was originally developed by Peptimmune Inc, and is a second-generation peptide copolymer, which is thought to enhance the regulatory response of the immune system. The drug is now ready to enter phase II clinical trials for the treatment of MS and possibly other autoimmune diseases.

MS is an inflammatory condition of the central nervous system. In young adults, it is the  most common, non-traumatic, disabling neurological disease, and it is estimated that around two million people have MS worldwide. The most common symptoms include blurred vision, numbness or tingling in the limbs and problems with strength and coordination, however these symptoms can vary.

Susan Herbert, head of Global Portfolio Development at Merck commented: "We are pleased to strengthen our development pipeline with the PI-2301 compound, which could play a valuable role in the treatment of this debilitating disease."

20th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics